Takeover row fails to derail Sanofi-Aventis and Genzyme business
This article was originally published in Scrip
Both Sanofi-Aventis and Genzyme have managed to retain a steady business course and avoid any potential distraction associated with their protracted takeover battle. Speaking at the JP Morgan Healthcare conference in San Francisco, both companies' CEOs spent their time highlighting progress in their core businesses, referring to the discussions between the two companies only in passing.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.